Cargando…
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomati...
Autores principales: | Di Palma, Martina, Gentilini, Elio, Masucci, Chiara, Micozzi, Alessandra, Turriziani, Ombretta, Mulè, Antonino, Foà, Robin, Martelli, Maurizio, D’Ettorre, Gabriella, Capria, Saveria, Chiaretti, Sabina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084234/ https://www.ncbi.nlm.nih.gov/pubmed/35615334 http://dx.doi.org/10.4084/MJHID.2022.043 |
Ejemplares similares
-
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018) -
Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Williams, Sherry, et al.
Publicado: (2018) -
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
por: Fracchiolla, Nicola Stefano, et al.
Publicado: (2023) -
Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018) -
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018)